JAK inhibitor receives PBS listing for rare blood cancer



Sponsored by Novartis Oncology

Jakavi® (ruxolitinib) has been listed on the PBS, making it the first JAK inhibitor to be approved by the TGA, and recommended by the PBAC, for myelofibrosis. PBS Listing Criteria From 1st February Jakavi has been reimbursed for intermediate-2 and high risk patients and int-1 patients with severe myelofibrosis-related symptoms intolerant, refractory or resistant to ...

Already a member?

Login to keep reading.

© 2021 the limbic